Skip to content
Menu

Mesoblast Limited MESO

Full chart Compare
Set alert

Price alert · MESO

All alert types
10.89 USD -0.29 (-2.59%)

Regular-session close

10.89 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

10.87 Day range 11.44
10.87 52-week range 21.50
YTD
-39.63%
1 year
-23.95%

Fundamental scorecard

8 of 25 checks passed on MESO’s reported financials

ValueGrowthProfitabilityHealthDividend

8of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Value 1 of 5

  • Failed:P/E below its own 5-year median No profit over FY 2026, so no P/E.
  • Failed:P/E under 20 No profit over FY 2026, so no P/E.
  • Passed:Price to sales below its own 5-year median Price to sales 11.8 against a 5-year median of 73.0.
  • Failed:Price to book below its own 5-year median Price to book 2.5 against a 5-year median of 1.4.
  • Failed:Free cash flow yield above 4% Free cash flow of -44.8M is -3.2% of the market value.

Growth 3 of 5

  • Passed:Revenue grew over the last year Revenue of 120M is +599.2% on the year before.
  • Passed:Revenue grew more than 5% a year over five years +74.5% a year from FY 2021 to FY 2026.
  • Passed:Earnings per share grew over the last year EPS -0.44 against -0.85 in the year before.
  • Failed:Earnings per share grew more than 5% a year over five years EPS -1.63 in FY 2021, -0.44 in FY 2026.
  • No data:Analysts expect higher earnings per share over the next year No analyst estimate.

Profitability 1 of 5

  • Failed:Profitable over the last year Net income of -57.5M over FY 2026.
  • Failed:Profitable in each of the last five fiscal years A profit in 0 of the last 5 fiscal years.
  • Failed:Return on equity above 15% Return on equity of -9.9%.
  • Passed:Net margin above its 5-year average Net margin of -47.8% against a 5-year average of -823.7%.
  • Failed:Free cash flow is at least 80% of net income No profit over FY 2026 to compare with.

Financial health 3 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 197M against short-term liabilities of 81.1M.
  • Passed:Short-term assets cover long-term liabilities Short-term assets of 197M against long-term liabilities of 124M.
  • Passed:Net debt under 40% of equity More cash than debt: 103M of cash against 8.10M of debt.
  • Failed:Operating cash flow covers at least 20% of debt Operating cash flow of -43.8M is -541.2% of debt.
  • Failed:Operating profit covers interest at least 3 times Operating profit is -1.4 times the interest expense.

Dividend 0 of 5

  • Failed:Pays a dividend No dividend paid.
  • Failed:Yield above 1.5% No dividend paid.
  • Failed:Pays out under 75% of profit No dividend paid.
  • Failed:Covered by free cash flow No dividend paid.
  • Failed:Not cut in the last five fiscal years No dividend paid.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What MESO owns and owes, as of Jun 30, 2026

Short term and long term

Balance sheet · 773M of assets

Debt, equity and cash by year

Now: 94.8M more cash than debt

Fiscal years. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

3.23 Safe zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

3 / 9 Weak

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

D+1 / 5 overall

  • DCF 1
  • Return on Equity 1
  • Return on Assets 1
  • Debt / Equity 1
  • P/E 1
  • P/B 1

Valuation

P/E -30.1×
P/S 14.5×
P/B 3.1×
P/FCF -39.2×
EV/EBITDA -42.7×
EV/Sales 15.2×
FCF Yield -2.6%

Profitability

Gross Margin 84.1%
Operating Margin -42.6%
Net Margin -47.8%
ROE -10.2%
ROIC -7.3%
ROA -7.5%

Growth (YoY)

Revenue 602.3%
Operating Income 17.5%
EPS (diluted) 46.7%
Free Cash Flow 11.8%

Financial Health

Current Ratio 2.4×
Quick Ratio 2.1×
Debt / Equity 0.2×
Net Debt / EBITDA -1.9×
Interest Coverage -2.2×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2026-06-30